-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome
(2457) Views (726) Full article downloads
Authors: Lars Heslet, Jakob Steen Andersen, Henrik Sengeløv, Björn Dahlbäck, Jorgen Dalsgaard-Nielsen
Published Date January 2007
Volume 2007:1(4) Pages 465 - 472
DOI: http://dx.doi.org/10.2147/BTT.S
Lars Heslet1, Jakob Steen Andersen1, Henrik Sengeløv2, Björn Dahlbäck3, Jorgen Dalsgaard-Nielsen4
1Department of Intensive Care ITA 4131; 2Department of Hematology L, University Hospital of Copenhagen, Rigshospitalet, Denmark; 3Department of Laboratory Medicin, Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden; 4Department of Clinical Biochemistry, Gentofte University Hospital, Hellerup, Denmark
Abstract: Acute respiratory distress syndrome (ARDS) is a potential lethal disease. At present time no evidence based intervention reduces mortality. The pathophysiology of ARDS include intraalveolar fibrin deposition, hyperinflammation and reduced cellular host defense in the airspace. The normal lung activates protein C (PC) to activated protein C (APC), in contrast to the ARDS lung where the PC-APC axis is disrupted. The lungs have targets for inhaled APC as illustrated by a patient case with ARDS, unresponsive to conventional therapy. After inhalation of 190 µg/kg of APC (Drotrecogin alpha activated) three times a day for seven days, a clear reduction in infiltrates on chest X-ray and a 138% increase in oxygenation capacity as reflected by the PaO2/FiO2 ratio was brought about. The patient, however, died later after cardiac arrest after suspected recurrence of the T-cell lymphoma. No local or systemic adverse effects was found related to the iAPC, during, after or at the time of death. It is suggested based on existing studies and the presented case that inhaled APC is a new treatment option in patients with ARDS – a hypothesis which should be substantiated in a larger series of ARDS patients.
Keywords: ARDS, activated protein C inhalation, pulmonary hemostasis, pulmonary host defense
Readers of this article also read:
Imatinib in the treatment of dermatofibrosarcoma protuberans
Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
Tipifarnib in the treatment of acute myeloid leukemia
The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells
α-L-iduronidase therapy for mucopolysaccharidosis type I
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Abatacept in difficult-to-treat juvenile idiopathic arthritis
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




